Molecular mechanism underlying the impact of vitamin D on disease activity of MS. (22nd August 2014)

• Record Type: Journal Article
• Authors: Munger, Kassandra L.; Köchert, Karl; Simon, Kelly C.; Kappos, Ludwig; Polman, Chris H.; Freedman, Mark S.; Hartung, Hans P.; Miller, David H.; Montalbán, Xavier; Edan, Gilles; Barkhof, Frederik; Pleimes, Dirk; Sandbrink, Rupert; Ascherio, Alberto; Pohl, Christoph
• Is Part Of: Annals of clinical and translational neurology. Volume 1:Number 8(2014)
• Page Start: 605
• Page End: 617
• Publication Date: 2014-08-22
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1002/acn3.91
• Languages: English
• ISSNs: 2328-9503

Abstract

<abstract abstract-type="main" id="acn391-abs-0001"> <title>Abstract</title> <sec id="acn391-sec-0001" sec-type="section"> <title>Objective</title> <p>Some previous studies suggest modest to strong effects of 25‐hydroxyvitamin D (25(OH)D) on multiple sclerosis (MS) activity. The objective of this study was to explore the mechanistic rationale that may explain potential clinical effects of 25(OH)D.</p> </sec> <sec id="acn391-sec-0002" sec-type="section"> <title>Methods</title> <p>This study measured serum 25(OH)D levels and global gene expression profiles over a course of up to 2 years in patients starting treatment with interferon beta‐1b (IFNB‐1b) after a clinically isolated syndrome. MS disease activity was assessed by the number of gadolinium‐enhancing lesions present on repeated magnetic resonance imaging (MRIs).</p> </sec> <sec id="acn391-sec-0003" sec-type="section"> <title>Results</title> <p>The number of gadolinium‐enhancing lesions was highly significantly associated with 25(OH)D levels. Conducting various systems‐level analyses on the molecular level, multiple lines of evidence indicated that 25(OH)D regulates expression dynamics of a large gene–gene interaction system which primarily regulates immune modulatory processes modulating MS activity. The vitamin D response element was significantly enriched in this system, indicating a direct regulation of this gene interaction network through the vitamin D receptor. With increasing 25(OH)D levels, resulting regulation of this system was associated with a decrease in MS activity. Within the complex network of genes that are regulated by 25(OH)D, well‐described targets of IFNB‐1b and a regulator of sphingosine‐1‐phosphate bioavailability were found. The 25(OH)D effects on MS activity were additively enhanced by IFNB‐1b.</p> </sec> <sec id="acn391-sec-0004" sec-type="section"> <title>Interpretation</title> <p>Here, we provide mechanistic evidence that an unbalanced 25(OH)D gene expression system may affect MS activity. Our findings support a potential benefit of monitoring and managing vitamin D levels (e.g., through supplementation) in early MS patients treated with IFN‐beta‐1b.</p> </sec> </abstract>